AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35996930
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and sulfasalazine (disease-modifying antirheumatic drugs)
Trial: 35996930
Drug: Korean patients
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean patients with PsA requiring biologics
Trial: 35998971
Drug: Perioperative mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative mental health intervention bundle (behavioural activation and medication optimisation)
Trial: 35999221
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (radiation-attenuated Plasmodium falciparum sporozoites)
Trial: 36000222
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulphate, 120 mg elemental iron)
Trial: 36000434
Drug: LDL-C ≥100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C ≥100 mg/dL
Trial: 36000434
Drug: LDL-C 70-99
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C 70-99 mg/dL
Trial: 36000747
Drug: Molecular adsorbent
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular adsorbent recirculating system (MARS) treatment
Trial: 36000783
Drug: Professional coaching
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional coaching (6 monthly sessions)
Trial: 36000783
Drug: Delayed intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed intervention (6 monthly sessions after 6 months)
Trial: 36000794
Drug: Neoadjuvant apalutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant apalutamide 240 mg once daily for 12 weeks
Trial: 36001108
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg on day 10 and fluconazole 200 mg once daily on days 11-23, with a single oral dose of fedratinib 100 mg on day 18
Trial: 36001108
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of fedratinib 100 mg on day 1
Trial: 36001228
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg intravenously every 3 weeks)
Trial: 36001228
Drug: Palliative SBRT
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative SBRT (30-50 Gy delivered daily over five fractions per week)
Trial: 36001228
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of palliative SBRT and camrelizumab
Trial: 36001750
Drug: High-dose glucagon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucagon (1.5 ng/kg/min, t = 270-450 min)
Trial: 36001750
Drug: Low-dose glucagon
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucagon (0.65 ng/kg/min, t = 0-270 min)
Trial: 36002226
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of bupivacaine
Trial: 36002243
Drug: Histotripsy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histotripsy treatment for hepatic tumors
Trial: 36002847
Drug: Preference-concordant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference-concordant treatment decisions
Trial: 36002847
Drug: Attributing a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attributing a lot of influence to treatment impact on recreation
Trial: 36004765
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction (MPFF) added to conservative treatment
Trial: 36005642
Drug: Multispecies Probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies Probiotic Treatment
Trial: 36006468
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) with a 75-g glucose dose
Trial: 36006468
Drug: Energy metabolism
RxNorm normalized name: Walgreens Vitamin B12 Energy Metabolism 100mcg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy metabolism response to OGTT
Trial: 36007963
Drug: Trametinib (T)
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib (T) 2 mg/day orally starting 1 week prior to durvalumab (D) 1500 mg intravenously every 4 weeks
Trial: 36007963
Drug: Tumor tissue
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor tissue flow cytometry at baseline (BL) and early on-treatment (OT) at week 4
Trial: 36008193
Drug: Intravesical pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical pembrolizumab (1-5 mg/kg for 2 hours)
Trial: 36008198
Drug: 24-h levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h levodopa-carbidopa intestinal gel (LCIG)
Trial: 36008198
Drug: 16-h levodopa-carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-h levodopa-carbidopa intestinal gel (LCIG)
Trial: 36011453
Drug: Professional Pharmaceutical
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional Pharmaceutical Service intervention
Trial: 36012885
Drug: Patient-reported treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported treatment experience
Trial: 36013098
Drug: Novel implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel implant system with low-speed (50 rpm) site preparation instruments used without irrigation and tri-oval, tapered implant.
Trial: 36015302
Drug: TDM arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDM arm (therapeutic drug monitoring)
Trial: 36015771
Drug: iPhone App
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: iPhone App for detecting prefrailty and sarcopenia syndromes, using sit-to-stand muscle power measured through a slow-motion video analysis mobile application in combination with muscle mass (calf circumference or upper mid-arm circumference).
Trial: 36016106
Drug: Ormutivimab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ormutivimab + vaccine
Trial: 36016106
Drug: HRIG +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRIG + vaccine
Trial: 36017088
Drug: Evolocumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (140 mg subcutaneous) on top of 10 mg/day rosuvastatin
Trial: 36017315
Drug: Insulin-induced hypoglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in control subjects
Trial: 36017315
Drug: Insulin-induced hypoglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-induced hypoglycemia (2mmol/l: 36mg/dl) in T2D subjects
Trial: 36028065
Drug: Proton radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiation therapy (proton-RT)
Trial: 36028065
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (not explicitly mentioned in the study but referenced for comparison)
Trial: 36028446
Drug: Dupilumab 200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200/300 mg every 2 weeks for 52 weeks
Trial: 36028757
Drug: Reduced-toxicity conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-toxicity conditioning regimen (RTC) using intravenous busulfan (3.2 mg/kg/d for 4 days) and fludarabine (30 mg/m2); specific dosage and duration provided.
Trial: 36028895
Drug: Cyclin-dependent kinase
RxNorm normalized name: Cyclin-dependent kinase (CDK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine therapy
Trial: 36029527
Drug: ABBV-383 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-383 (administered intravenously over 1-2 hours once every 3 weeks)
Trial: 36029527
Drug: ABBV-383 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-383 (60 mg dose in dose expansion cohort)
Trial: 36029527
Drug: ABBV-383 (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-383 (≥ 40 mg in dose escalation plus dose expansion cohorts)
Trial: 36029725
Drug: Medication administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication administration based on CPIC Level A evidence.
Trial: 36030342
Drug: Analgesics (including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics (including opioids, gabapentinoids, and paracetamol) dispensed to adolescents from age 15
Trial: 36030342
Drug: Benzodiazepines and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines and z-hypnotics
Trial: 36030342
Drug: Overall prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall prescription drugs
Trial: 36031093
Drug: Infliximab (IFX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (IFX), median initial dose 9.9 mg/kg
Trial: 36031390
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early antiretroviral treatment
Trial: 36034306
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment with Brainer and physical training with jDome
Trial: 36034306
Drug: Cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive treatment with Brainer and physical training with a classic bicycle
Trial: 36034411
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (initiating bevacizumab or corticosteroids treatment within three months after RN diagnosis)
Trial: 36034411
Drug: Watch-and-wait policy
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watch-and-wait policy (no early treatment)
Trial: 36035961
Drug: Higher magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher magnesium intake (>320 mg/day)
Trial: 36035961
Drug: Higher magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher magnesium intake (>320 mg/day) in diuretic users
Trial: 36036663
Drug: Fresh solution
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh solution exchange
Trial: 36036663
Drug: Reuse of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reuse of original solution
Trial: 36036971
Drug: Set Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Set Daily Reminders
Trial: 36037793
Drug: Pain ratings
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain ratings and the amount of opioid analgesics consumed after the first and second TKAs
Trial: 36038699
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of 0.9% saline over 30 min on two consecutive days
Trial: 36041227
Drug: Oral microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiota assessment
Trial: 36041755
Drug: Any antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antiarrhythmic therapies (AATs) including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription.
Trial: 36042527
Drug: Induced hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced hypertension treatment
Trial: 36043184
Drug: 30 μg of
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 μg of SCB-2019 + CpG + aluminium hydroxide
Trial: 36043184
Drug: SCB-2019 formulations
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 formulations
Trial: 36043728
Drug: French version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: French version of the Bath Ankylosing Spondylitis Global score (BAS-G)
Trial: 36044285
Drug: Unhealthy alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unhealthy alcohol use (AUDIT-C ≥3 for women or ≥4 for men; PEth ≥50 ng/mL)
Trial: 36044285
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol use (AUDIT-C 1-2 for women or 1-3 for men; PEth 8 ≥ 50 ng/mL)
Trial: 36044285
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alcohol consumption (self-report and PEth <8 ng/mL)
Trial: 36044385
Drug: TMTV/Eastern Cooperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMTV/Eastern Cooperative Oncology Group-PS combination
Trial: 36044388
Drug: Tisagenlecleucel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel plus pembrolizumab (200 mg every 21 days for up to 6 doses)
Trial: 36044526
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg) plus Bevacizumab (7.5 mg/kg) administered every 3 weeks
Trial: 36044870
Drug: Lanreotide autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel (LAN) 120 mg every 28 days and temozolomide (TMZ) 250 mg/day for 5 consecutive days every 28-day cycle
Trial: 36045316
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid 500 mg three times daily
Trial: 36046613
Drug: Sick-day protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sick-day protocol administered via interactive voice response system (IVRS)
Trial: 36048266
Drug: Consolidation durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation durvalumab immune checkpoint inhibitor (ICI) therapy
Trial: 36048266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of COPD with perfused lung radiomics size features
Trial: 36048266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of COPD with perfused lung radiomics shape features
Trial: 36048535
Drug: Olaparib in
RxNorm normalized name: Product containing olaparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib in combination with buparlisib (BKM120)
Trial: 36048970
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogue (NA) therapy withdrawal
Trial: 36049654
Drug: Rezivertinib (BPI-7711)
RxNorm normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezivertinib (BPI-7711) at 180 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: 36050737
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of noradrenaline
Trial: 36050804
Drug: Perioperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative oral nutritional support (ONS)
Trial: 36050896
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block (SGB) combined with prolonged exposure therapy (PE)
Trial: 36051040
Drug: Dose-dense immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense immunochemotherapy with early systemic CNS prophylaxis
Trial: 36051045
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg by mouth once daily in four-week cycles for up to 24 cycles
Trial: 36052502
Drug: Enzalutamide, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide, a second-generation AR-targeted therapy
Trial: 36052732
Drug: Morreton virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morreton virus (MORV) at a dose of 1 × 10 7 TCID 50
Trial: 36052732
Drug: Morreton virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morreton virus (MORV) at a dose of 10 10 TCID 50
Trial: 36052732
Drug: Vesicular stomatitis
RxNorm normalized name: Vesicular stomatitis virus Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesicular stomatitis virus (VSV) at a dose of 1 × 10 8 TCID 50
Trial: 36053449
Drug: Extended regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP) taken daily for up to 120 consecutive days
Trial: 36053558
Drug: Web-based decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based decision aid (DA) for treatment planning of SKMs
Trial: 36053624
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) in the first postnatal week
Trial: 36053632
Drug: Ibuprofen (n=3857)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (n=3857)
Trial: 36053632
Drug: Overall PDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall PDA treatment (n=5721)
Trial: 36054234
Drug: pp65-specific TCR-T
RxNorm normalized name: Neoantigen specific TCR-T cell therapy
DrugBank: Neoantigen specific TCR-T cell therapy (DB17458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pp65-specific TCR-T cell therapy
Trial: 36054490
Drug: CV301 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV301 in combination with nivolumab (C1)
Trial: 36054490
Drug: CV301 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV301 in combination with pembrolizumab (C2)
Trial: 36055922
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of triamcinolone acetonide
Trial: 36055962
Drug: Dietary acrylamide
RxNorm normalized name: acrylamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary acrylamide intake (mean ± SD: 30.1 ± 21.9 µg/d)
Trial: 36057175
Drug: Astra-Zeneca vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astra-Zeneca vaccine and Sputnik V vaccine (complete vaccination)
Trial: 36057544
Drug: IgM(N) antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM(N) antibody levels in infected healthcare workers
Trial: 36057544
Drug: IgG(N) antibody
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG(N) antibody levels in infected healthcare workers
Trial: 36057544
Drug: IgG(S) antibody
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG(S) antibody levels in infected healthcare workers
Trial: 36057544
Drug: Kinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetics of IgM(N) and IgG(N) antibodies
Trial: 36057544
Drug: Kinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetics of IgG(S) antibodies
Trial: 36057544
Drug: Kinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetics of IgM and IgG antibodies
Trial: 36058111
Drug: Community sanitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community sanitation coverage of at least one latrine per compound within 50m
Trial: 36058810
Drug: Biomarker use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker use in treatment decisions
Trial: 36058925
Drug: Concentrated transdiagnostic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated transdiagnostic, interdisciplinary group treatment delivered during 5 consecutive days.
Trial: 36059138
Drug: Ceftaroline 600
RxNorm normalized name: ceftaroline 600 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftaroline 600 mg every 12 hours